Atropine

French, Richard H.; Walter, Frank G.

doi:10.1007/978-3-319-17900-1_153

Cited by 2 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the acute setting, a critically poisoned patient with bradyarrhythmia should be treated with atropine. 20 …”

Section: Discussionmentioning

confidence: 99%

“…In the acute setting, a critically poisoned patient with bradyarrhythmia should be treated with atropine. 20 Eliglustat is predominantly metabolized by CYP2D6 and to a lesser extent by CYP3A4. 16 Concomitant medicines inhibiting CYP2D6 or CYP3A4 activity may increase significantly eliglustat plasma concentrations.…”

Section: Discussionmentioning

confidence: 99%

“…Bradycardia symptoms may include syncope or dizziness. In the acute setting, a critically poisoned patient with bradyarrhythmia should be treated with atropine 20 …”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Suicidal attempt with eliglustat overdose

2022

View full text Add to dashboard Cite

Eliglustat is an orphan medicine used for long‐term treatment of Gaucher disease type 1 (GD1) in adults. GD1 is a genetic condition, in which glucosylceramide builds up in the body, typically in liver, spleen, and bone. Clinical signs and symptoms of the disease are anemia, tiredness, easy bruising, hepatosplenomegaly, bone pain, and fractures. Eliglustat works by blocking glucosylceramide synthase (substrate reduction therapy). This medicine is subject to additional safety monitoring by regulatory authorities in the European Union. Scientific literature on eliglustat overdose is not available. We herein describe successful treatment of a suicidal attempt with massive eliglustat overdose. A 29‐year‐old female with GD1, a poor metabolizer of cytochrome P450 2D6 on a recommended daily dose of 84 mg of eliglustat, had taken 94 capsules of eliglustat (84 mg per capsule). One hour after ingestion of almost 8 g of eliglustat, the patient suffered from somnolence, severe bradycardia (37 bpm), and hypotension (systolic blood pressure of 70 mm Hg). After intravenous administration of atropine (1 mg) and cafedrine/theoadrenaline (100 mg/5 mg) by the called emergency physician, the patient resolved gradually. She remained 24 h with stable hemodynamics at a nearby intensive care unit. During continuous ECG monitoring, increased frequency of supraventricular ectopic activity and a first‐degree atrioventricular block were observed. To our knowledge, this is the first case report on a suicidal attempt with eliglustat.

show abstract

“…In the acute setting, a critically poisoned patient with bradyarrhythmia should be treated with atropine. 20 …”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Suicidal attempt with eliglustat overdose

2022

View full text Add to dashboard Cite

show abstract

“…Atropine, a naturally occurring alkaloid from the Atropa belladonna plant, is used as anticholinergic medication to slow heart rate and to treat certain types of nerve agent and pesticide poisonings [ 1 ]. Atropine works as a competitive antagonist for the muscarinic acetylcholine receptors (mAChRs) and inhibits the parasympathetic nervous system via blocking of these receptors [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Atropine Is a Suppressor of Epithelial–Mesenchymal Transition (EMT) That Reduces Stemness in Drug-Resistant Breast Cancer Cells

Ahmed

Alkuwayti

Ibrahim

2022

IJMS

View full text Add to dashboard Cite

Atropine (ATR) is extracted from a belladonna plant that belongs to a class of anticholinergic drugs and is therefore involved in the treatment of the overdose of cholinergic drugs or mushroom poisoning. It is a well-known blocker of muscarinic acetylcholine receptors (mAChRs) that are expressed in various tumor cells, including breast tumors from animal and human origin, but it has yet to be recommended as an anticancer drug. Our in silico docking analysis indicates that atropine has a roust virtual binding, with a stable binding energy, to two major signaling molecules involved in EMT regulation: E-cad and ZEB-2. For both, the gene and the protein expression level results show that atropine is an effective molecule in reducing epithelial–mesenchymal transition (EMT) and colony formation induced by TGF-B or carboplatin in both the mesenchymal-like cell line MDA-MB-231 and the epithelial-like cell line T47D. We conclude that atropine as a potential suppressor of EMT could be co-administrated with other chemotherapeutic drugs to reduce stemness in drug-resistant breast tumor cells.

show abstract

Atropine

Cited by 2 publications

References 29 publications

Suicidal attempt with eliglustat overdose

Suicidal attempt with eliglustat overdose

Atropine Is a Suppressor of Epithelial–Mesenchymal Transition (EMT) That Reduces Stemness in Drug-Resistant Breast Cancer Cells

Contact Info

Product

Resources

About